Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine (1-(1-(3-Methoxyphenyl)cyclohexyl)piperidine) in Schedule I

The DEA placed 3-methoxyphencyclidine, a dissociative anesthetic with no accepted medical use, into Schedule I, impacting any potential research involving this substance and clarifying its legal status separate from cannabis.

Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I

The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as an adulterant in cannabis products, into Schedule I, making it illegal and impacting patient safety/clinician awareness.

Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act

The DEA placed five benzodiazepine analogs into Schedule I, impacting their availability and potentially prompting clinicians to reconsider treatment plans involving these substances as alternatives to cannabis for anxiety or insomnia.

Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I

The DEA temporarily placed 2-fluorodeschloroketamine into Schedule I, potentially impacting research and clinical use should this substance be considered as an adjunct therapy alongside cannabis for certain conditions.

Schedules of Controlled Substances: Placement of 4-Fluoroamphetamine in Schedule I

The DEA placed 4-fluoroamphetamine into Schedule I, potentially impacting research access and clinical use should similar scheduling actions occur for cannabinoids or related compounds.

Schedules of Controlled Substances: Placement of N-Pyrrolidino Metonitazene and N-Pyrrolidino Protonitazene in Schedule I

The DEA placed potent synthetic opioids N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting cannabis clinicians who may encounter patients with co-prescribed medications or polysubstance use disorders.

Schedules of Controlled Substances: Placement of N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene in Schedule I

The DEA placed two synthetic opioids, N-Desethyl Isotonitazene and N-Piperidinyl Etonitazene, into Schedule I, impacting clinicians needing to differentiate these substances from cannabis when evaluating patient toxicology reports or substance use disorders.

Schedules of Controlled Substances: Placement of 4F-MDMB-BUTICA, ADB-4en-PINACA, 5F-EDMB-PICA, and MMB-FUBICA in Schedule I

The DEA placed four synthetic cannabinoids into Schedule I, classifying them as having a high potential for abuse and no accepted medical use, impacting clinical practice and legal considerations regarding cannabinoid products.

Schedules of Controlled Substances: Temporary Placement of Bromazolam in Schedule I

The DEA temporarily placed bromazolam, a benzodiazepine sometimes found as adulterant in cannabis products, into Schedule I, impacting its legality and clinical use.

Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I

The DEA placed cumyl-pegaclone, a synthetic cannabinoid, into Schedule I, meaning it has a high potential for abuse and no currently accepted medical use in the United States.

Schedules of Controlled Substances: Placement of 4-Chloromethcathinone in Schedule I

The DEA placed 4-chloromethcathinone, a synthetic cathinone unrelated to cannabis, into Schedule I, impacting clinicians by restricting research and patient access should it be encountered in clinical practice.

Schedules of Controlled Substances: Temporary Placement of Ethyleneoxynitazene, Methylenedioxynitazene, 5-Methyl Etodesnitazene, N-Desethyl Etonitazene, N-Desethyl Protonitazene, N,N-Dimethylamino Etonitazene, and N-Pyrrolidino Isotonitazene in Schedule I

The DEA temporarily scheduled six synthetic opioids as Schedule I controlled substances, impacting clinicians who may encounter these substances in patient toxicology screens or differential diagnoses.

Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I

The DEA placed synthetic cannabinoid MDMB-4en-PINACA into Schedule I, classifying it as having a high potential for abuse and no accepted medical use, impacting clinical practice and patient access.

Schedules of Controlled Substances: Placement of Seven Specific Fentanyl-Related Substances in Schedule I

This temporary scheduling action does not directly impact cannabis but clarifies federal control over fentanyl analogs, potentially affecting pain management discussions with patients considering alternatives.

Schedules of Controlled Substances: Temporary Placement of N-pyrrolidino metonitazene and N-pyrrolidino protonitazene in Schedule I

The DEA temporarily placed N-pyrrolidino metonitazene and N-pyrrolidino protonitazene into Schedule I, impacting clinicians by restricting their use and potentially raising awareness of novel synthetic opioids appearing in the unregulated cannabis market.

Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I of the Controlled Substances Act

The DEA placed five benzodiazepine analogs into Schedule I, impacting potential clinical considerations for practitioners evaluating patient-reported use of these substances alongside cannabis.

Exempt Chemical Preparations Under the Controlled Substances Act

A 2023 rule clarifies that hemp-derived extracts containing no more than 0.3% delta-9 THC are exempt from Controlled Substances Act regulation, impacting legal access for some patients and clinicians.

Schedules of Controlled Substances: Temporary Placement of Seven Benzimidazole-Opioids in Schedule I

The DEA temporarily placed seven synthetic opioids in Schedule I, impacting research and potentially diverting attention/resources from cannabis-based pain management studies.

Specific Listing for Hexahydrocannabinol, A Currently Controlled Schedule I Substance

The DEA proposed placing hexahydrocannabinol (HHC), a synthetic cannabinoid not found naturally in cannabis, into Schedule I alongside other controlled substances like marijuana.

These regulatory actions reflect the ongoing challenge of controlling novel synthetic drugs that emerge faster than formal scheduling processes can accommodate, with temporary placements indicating expedited responses to imminent public health threats. The predominance of synthetic cannabinoids, benzodiazepines, nitazenes, and fentanyl analogs suggests that clandestine chemists continue to exploit structural variations to circumvent existing controls while maintaining pharmacological potency. Clinicians should remain vigilant for emerging intoxication patterns and withdrawal syndromes from these agents, as their novelty often means limited safety data and unpredictable toxicity profiles in patient populations.